# Study to Assess Change in Disease Activity and Adverse Events of RINVOQ in Adult Participants With Ankylosing Spondylitis in the Real-World Japan

> **NCT05609643** · — · COMPLETED · sponsor: **AbbVie** · enrollment: 69 (actual)

## Conditions studied

- Ankylosing Spondylitis

## Interventions

_None listed._

## Key facts

- **NCT ID:** NCT05609643
- **Lead sponsor:** AbbVie
- **Sponsor class:** INDUSTRY
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** COMPLETED
- **Start date:** 2022-07-06
- **Primary completion:** 2025-12-11
- **Final completion:** 2026-01-29
- **Target enrollment:** 69 (ACTUAL)
- **Last updated:** 2026-02-17


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05609643

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05609643, "Study to Assess Change in Disease Activity and Adverse Events of RINVOQ in Adult Participants With Ankylosing Spondylitis in the Real-World Japan". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT05609643. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*